Aduro is developing novel therapies that induce highly targeted, potent and sustained immune responses against a variety of cancers. We have three diverse immunotherapy platforms – LADD (live, attenuated, double-deleted Listeria mononcytogenes), CDNs (cyclic dinucleotides) and B-select antibodies (B-select) that we believe are key to our fulfillment of our mission to stay at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination; that make transformative advances in the treatment of challenging diseases.


Our lead technology platform is LADD (live-attenuated, double-deleted Listeria mononcytogenes), and our lead product candidates use LADD-based agents both as monotherapies and in combination with existing conventional and newly emerging cancer therapies, including GVAX, chemotherapy, and checkpoint inhibitors.


Aduro has a complementary technology platform based on CDNs (cyclic dinucleotides). These small molecules adjuvants help stimulate the important STING pathway inside immune cells. Aduro has developed proprietary modifications of these naturally occurring compounds to enhance their cancer-fighting characteristics.

B-select Antibodies

Aduro also has a portfolio of therapeutic antibodies that are being developed based on the B-select platform. This technology is based on clonal expansion in culture of B cells (antibody producing cells) isolated from spleen or lymph nodes of immunized mice, followed by immortalization of select B cells through miniaturized electrofusion. This approach is capable of rescuing one of every two antigen-specific B cells induced in mice. This unprecedented efficiency enables exploration of the full induced repertoire of B cells to uncover unique antibodies with pre-specified function (the ‘needle in the haystack’).

Enhancing Therapeutics Strengh through Combinations

Breadth of potential combinations with conventional and novel therapies.